Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.85 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.55 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.54 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.52 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL225375 | 0.96 | GPR119 (0.91) | GPR119HRH3ALK | |
| SCHEMBL2573353 | 0.92 | GPR119 (1.00) | GPR119HRH3ALK | |
| SCHEMBL2573355 | 0.92 | GPR119 (1.00) | GPR119HRH3ALK | |
| SCHEMBL24117836 | 0.89 | GPR119 (0.79) | GPR119HRH3ALK | |
| SCHEMBL5091205 | 0.89 | GPR119 (0.79) | GPR119HRH3ALK | |
| SCHEMBL31632594 | 0.89 | GPR119 (0.79) | GPR119HRH3ALK | |
| SCHEMBL2540012 | 0.86 | GPR119 (0.64) | GPR119PTPN2PTPN1PTPN6 | |
| SCHEMBL21825090 | 0.84 | GPR119 (0.71) | GPR119HRH3ALK | |
| SCHEMBL19901156 | 0.84 | HRH3 (0.62) | GPR119HRH3CHEK2 | |
| SCHEMBL14464240 | 0.84 | GPR119 (0.61) | GPR119HRH3ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702388-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2023-07-18 | — | — | US | claimed |
| US-20210230116-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2021-07-29 | — | — | US | claimed |
| EP-3310441-B1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | 89BIO LTD (IL) | 2020-07-29 | — | — | EP | claimed |
| US-20250257035-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2025-08-14 | — | — | US | disclosed |
| US-12098130-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2024-09-24 | — | — | US | disclosed |
| US-20230391723-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2023-12-07 | — | — | US | disclosed |
| US-11702388-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2023-07-18 | — | — | US | disclosed |
| US-20210230116-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2021-07-29 | — | — | US | disclosed |
| CN-107847765-B | 1, 4-substituted piperidine derivatives | 89生物有限公司 | 2021-05-04 | — | — | CN | disclosed |
| US-10851057-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2020-12-01 | — | — | US | disclosed |
| EP-3310441-B1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | 89BIO LTD (IL) | 2020-07-29 | — | — | EP | disclosed |
| US-20180179159-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON LLC | 2018-06-28 | — | — | US | disclosed |
| EP-3310441-A1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | Cephalon, Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| US-9902696-B2 | 1,4-substituted piperidine derivatives | CEPHALON, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-20160368874-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON LLC | 2016-12-22 | — | — | US | disclosed |
| WO-2016205633-A1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| WO-2010048149-A2 | HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010048149-A2 | HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| US-7638531-B2 | Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-20070167435-A1 | Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257035-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | GPR119 223/4885HRH3 4067/4885ALK 2503/4885 |
| US-20230391723-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | GPR119 223/4885HRH3 4067/4885ALK 2503/4885 |
| US-20160368874-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | FASN, CES1, CPT1A | GPR119 223/4885HRH3 4067/4885ALK 2503/4885 |
| US-20210230116-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | GPR119 223/4885HRH3 4067/4885ALK 2503/4885 |
| US-20070167435-A1 | Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists | HRH4, HRH3, HRH2 | GPR119 43/4885HRH3 2/4885ALK 697/4885 |
| US-11702388-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | GPR119 223/4885HRH3 4067/4885ALK 2503/4885 |
| US-12098130-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | GPR119 223/4885HRH3 4067/4885ALK 2503/4885 |
| US-10851057-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | GPR119 223/4885HRH3 4067/4885ALK 2503/4885 |
| US-20180179159-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | FASN, CES1, CPT1A | GPR119 225/4885HRH3 4144/4885ALK 2503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.